Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Die Nephrologie
Erschienen in: Der Nephrologe 4/2013

01.07.2013 | Leitthema

Hepatorenales Syndrom

verfasst von: M. Hinz, O. Witzke, G. Gerken, Prof. Dr. A. Canbay

Erschienen in: Die Nephrologie | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Patienten mit hepatorenalem Syndrom benötigen wegen der schlechten Prognose eine schnelle Identifikation ihrer Krankheit und eine prompte Zuordnung als Kandidaten für eine orthotope Lebertransplantation (OLT). Eine erfolgreiche Vasokonstriktortherapie, kombiniert mit einer Albumintherapie, erhöht die Überlebenswahrscheinlichkeit bei der Überbrückung der kritischen Wartefrist bis zur Transplantation und führt zu einer verbesserten renalen Funktion nach der OLT. In selektierten Fällen kann die Anlage eines TIPS oder die Nierenersatztherapie eine wichtige therapeutische Option darstellen. In den Fällen, bei denen Prognosefaktoren eine Persistenz der renalen Dysfunktion nach der Transplantation vorhersagen, kann eine sequenzielle oder simultane Leber-Nieren-Transplantation indiziert sein.
Literatur
1.
Garcia-Tsao G, Parik CR, Viola A (2008) Acute kidney injury in cirrhosis. Hepatology 48:2064–2077PubMedCrossRef
2.
Hecker R, Sherlock S (1956) Electrolyte and circulatory changes in terminal liver failure. Lancet 271:1121–1125PubMedCrossRef
3.
Schrier R, Arroyo V, Bernadi M et al (1988) Peripheral arterial vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8:1151–1157PubMedCrossRef
4.
Planas R, Montoliou S, Balleste B et al (2006) Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 4:1385–1394PubMedCrossRef
5.
Fernandez J, Navasa M, Planas R et al (2007) Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 133:818–824PubMedCrossRef
6.
Alessandria C, Ozdogan O, Guevara M et al (2005) MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 41(6):1282–1289PubMedCrossRef
7.
Arroyo V, Gines P, Gerbes A et al (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 23(1):164–176PubMedCrossRef
8.
Salerno F, Gerbes A, Gines P et al (2007) Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 56(9):1310–1318PubMed
9.
Salerno F, Cazzaniga M, Merli M et al (2011) Diagnosis, treatment, and survival of patients with hepatorenal syndrome: a survey on daily medical practice. J Hepatol 55:1241–1248PubMedCrossRef
10.
Wong F (2012) Recent advances in our understanding of hepatorenal syndrome. Nat Rev Gastroenterol Hepatol 9:382–391PubMedCrossRef
11.
Wadei HM (2012) Hepatorenal syndrome: a critical update. Semin Respir Crit Care Med 33:55–69PubMed
12.
Arroyo V, Fernandez J, Gines P (2008) Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 28:81–95PubMedCrossRef
13.
Follo A, Llovet JM, Navasa M et al (1994) Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 20:1495–1501PubMedCrossRef
14.
Leung W, Al Beshir M, Marquez M et al (2012) Is type 1 hepatorenal syndrome reversible after liver transplantation? J Hepatol 56(Suppl 2):S258–S259CrossRef
15.
Sort P, Navasa M, Arroyo V et al (1999) Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341(6):403–409PubMedCrossRef
16.
Mandal AK, Lansing M, Fahmy A (1982) Acute tubular necrosis in hepatorenal syndrome: an electron microscopic study. Am J Kidney Dis 2:363–374PubMed
17.
Trawalé JM, Paradis V, Rautou PE et al (2010) The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int 30:725–732PubMedCrossRef
18.
Wong F, Nadim MK, Kellum JA et al (2011) Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 60(5):702–709PubMedCrossRef
19.
Cholangitas E, Senzolo M, Patch D et al (2009) Cirrhotics admitted to intensive care unit: the impact of acute renal failure on mortality. Eur J Gastroenterol Hepatol 21(7):744–750CrossRef
20.
Martin PY, Gines P, Schrier RW (1998) Nitric oxide as a mediator of hemodynamic abnormalities and sodium water retention in cirrhosis. N Engl J Med 339:533–541PubMedCrossRef
21.
Van Landeghem L, Laleman W, Vander Elst I et al (2009) Carbon monoxide produced by intrasinusoidally located haem-oxygenase-1 regulates the vascular tone in cirrhotic rat liver. Liver Int 29:650–660CrossRef
22.
De las Heras D, Fernandez J, Gines P et al (2003) Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatology 38(2):451–459
23.
Bátkai S, Járai Z, Wagner JA et al (2001) Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 7:827–832PubMedCrossRef
24.
Caraceni P, Viola A, Piscitelli F et al (2010) Circulating and hepatic endocannabinoid related molecules in patients with cirrhosis. Liver Int 30(6):816–825PubMedCrossRef
25.
Wiest R, Groszmann RJ (2002) The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 35:478–491PubMedCrossRef
26.
Groszman RJ (1994) Hyperdynamic circulation of liver disease 40 years later: pathophysiolgy and clinical consequences. Hepatology 20:1359–1363CrossRef
27.
Wong F, Massie D, Colman J, Dudley F (1993) Glomerular hyperfiltration in patients with well-compensated alcoholic cirrhosis. Gastroenterology 104:884–889PubMed
28.
Møller S, Hobolth L, Winkler C et al (2011) Determinants of the hyperdynamic circulation and central hypervolemia in cirrhosis. Gut 60(9):1254–1259PubMedCrossRef
29.
Kiszka-Kanowitz M, Henriksen JH, Møller S, Bendtsen F (2001) Blood volume distribution in patients with cirrhosis: aspects oft he dual-head gamma camera technique. J Hepatol 35(5):605–612PubMedCrossRef
30.
Govindarajan S, Nast CC, Smith WL et al (1987) Immunohistochemical distribution of renal prostaglandin endoperoxide synthase and prostacyclin synthase: diminished endoperoxide synthase in the hepatorenal syndrome. Hepatology 7(4):654–659PubMedCrossRef
31.
Chandok N, Watt KDS (2010) Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc 85(5):451–458PubMedCrossRef
32.
Moreau R, Lebrec D (2007) Diagnosis and treatment of acute renal failure in patients with cirrhosis. Best Pract Res Clin Gastroenterol 21(1):111–123PubMedCrossRef
33.
Heller J, Sogni P, Barriere E et al (2000) Effects of lipopolysaccharides on TNF-α production, hepatic NOS2 activity, and hepatic toxicity in rats with cirrhosis. J Hepatol 33:376–381PubMedCrossRef
34.
Albilios A, Hera A de la, Gonzales M et al (2003) Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune- and haemodynamic derangement. Hepatology 37:208–217CrossRef
35.
Garcia-Tsao G (2004) Bacterial infections in cirrhosis. Can J Gastroenterol 18:405–406PubMed
36.
Bosch J, Abraldes JG, Fernandez M, Garcia-Pagan JC (2010) Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol 53:558–567PubMedCrossRef
37.
Tsai MH, Peng YS, Chen Y et al (2006) Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology 43(4):673–681PubMedCrossRef
38.
Fernandez J, Escorsell A, Zabalza M et al (2006) Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. Hepatology 44(5):1288–1295PubMedCrossRef
39.
Stadlbauer V, Wright GA, Banaji M et al (2008) Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterolgy 134(1):111–119CrossRef
40.
Fasolato S, Angeli P, Dallagnese L et al (2007) Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 45:223–229PubMedCrossRef
41.
Lebrec D, Thabut D, Oberti F et al (2010) Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 138:1755–1762PubMedCrossRef
42.
Akriviadis E, Botla R, Briggs W et al (2000) Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind placebo controlled trial. Gastroenterology 119:1637–1648PubMedCrossRef
43.
Whitfield K, Rambaldi A, Wetterslev J, Gluud C (2009) Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 4:CD 007339
44.
Gines A, Fernandez-Esparrach G, Monescillo A et al (1996) Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 111(4):1002–1010PubMedCrossRef
45.
Garcia-Compean D, Blanc P, Larrey D et al (2002) Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial. Ann Hepatol 1(1):29–35PubMed
46.
Olsen JC, Kamath PS (2011) Acute-on-chronic liver failure: concept, natural history, and prognosis. Curr Opin Crit Care 17:165–169CrossRef
47.
Eckart J, Forst H, Briegel J (Hrsg) (2011) Intensivmedizin: Kompendium und Repetitorium zur interdisziplinären Weiter- und Fortbildung, 45. Ergänzungslieferung 9/11. Ecomed, Heidelberg
48.
Chavez-Tapia NC, Barrientos-Gutierrez T, Telles-Avila F et al (2011) Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding – an updated Cochrane review. Aliment Pharmacol Ther 34:509–518PubMedCrossRef
49.
Rajekar H, Chawla Y (2011) Terlipressin in hepatorenal syndrome: evidence for present indications. J Gastroenterol Hepatol 26(Suppl 1):109–114PubMedCrossRef
50.
Aronsen KF, Wetterlin S, Emas S et al (1975) Die Wirkung von Triglycyl-Lysin-Vasopressin auf Kontrollpersonen und Patienten mit Blutungen des oberen Gastrointestinaltraktes. Klin Wschr 53:747–753PubMedCrossRef
51.
Ryckwaert F, Virsolvy A, Fort A et al (2009) Terlipressin, a provasopressin drug exhibits direct vasoconstrictor properties: consequences on heart perfusion and performance. Crit Care Med 37(3):876–881PubMedCrossRef
52.
Arroyo V, Fernandez J (2011) Management of hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol 7(9):517–526PubMed
53.
Gerbes AL, Huber E, Gülberg V (2009) Terlipressin for hepatorenal syndrome. Continuous infusion as an alternative to i.v. bolus administration. Gastroenterology 137:1179–1181PubMedCrossRef
54.
Sanyal AJ, Boyer T, Garcia-Tsao G et al (2008) A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 134:1360–1368PubMedCrossRef
55.
Martin-Llahi M, Pepin M, Guevara M et al (2008) Terlipressin and albumin vs. albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 134:1352–1359PubMedCrossRef
56.
Moreau R, Durand F, Poynard T et al (2002) Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122(4):923–930PubMedCrossRef
57.
Colle I, Durand F, Pessione F et al (2002) Clinical course, predictive factors, and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis. J Gastroenterol Hepatol 17(8):882–888PubMedCrossRef
58.
Ortega R, Gines P, Uriz J et al (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 36(4):941–948PubMed
59.
Uriz J, Gines P, Cardenas A et al (2000) Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 33(1):43–48PubMedCrossRef
60.
Alessandria C, Venon WD, Marcano A et al (2002) Renal failure in cirrhosis patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 14(2):1363–1368PubMedCrossRef
61.
Solanki P, Chawla A, Garg R et al (2003) Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized, placebo-controlled clinical trial. J Gastroenterol Hepatol 18(2):152–156PubMedCrossRef
62.
Muñoz LE, Alcalá EG, Cordero P et al (2009) Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico. Ann Hepatol 8:207–2011PubMed
63.
Angeli P, Morando F (2010) Optimal management of hepatorenal syndrome in patients with cirrhosis. Hepatic Med 2:87–98CrossRef
64.
Hinz M, Wree A, Jochum C et al (2013) High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome. Ann Hepatol 12(1):92–99PubMed
65.
Testro AG, Wongseelashote S, Angus PW, Gow PJ (2008) Longterm outcome of patients treated with terlipressin for type 1 and 2 hepatorenal syndrome. J Gastroenterol Hepatol 23:1535–1540PubMedCrossRef
66.
Boyer TD, Sanyal AJ, Garcia-Tsao G et al (2011) Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol 55:315–321PubMedCrossRef
67.
Nazar A, Pereira GH, Guevara M et al (2010) Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 51(1):219–226PubMedCrossRef
68.
Gluud LL, Christensen K, Christensen E, Krag A (2010) Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 51:576–584PubMedCrossRef
69.
Sagi SV, Mittal S, Kasturi KS, Sood GK (2010) Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol 25:880–885
70.
Caraceni P, Santi L, Mirici F et al (2011) Long-term treatment of hepatorenal syndrome as bridge to liver transplantation. Dig Liver Dis 43:242–245PubMedCrossRef
71.
Ganne-Carrie N, Hagendue A, Mathurin P et al (1996) Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation. Dig Dis Sci 41(6):1054–1056PubMedCrossRef
72.
Rice JP, Skagen C, Said A (2011) Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin. Transplantation 91:1141–1147PubMedCrossRef
73.
Angeli P, Volpin R, Gerunda G et al (1999) Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 29:1690–1697PubMedCrossRef
74.
Wong F, Pantea L, Sniderman K (2004) Midodrine, octreotide, albumin and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 40:55–64PubMedCrossRef
75.
Esrailian E, Pantangco ER, Kyulo NL et al (2007) Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 52:742–748PubMedCrossRef
76.
Cavallin M, Merli M, Fasolato S et al (2011) Terlipressin and albumin vs. midodrine plus octreotide and albumin in the treatment of hepatorenal syndrome in patients with cirrhosis: results of a controlled clinical trial by the Italian Association for the Study of the Liver. (Abstract LB-2). Hepatology 54(Suppl 1):1426A
77.
Singh V, Gosh S, Singl B et al (2012) Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol 56:1293–1298PubMedCrossRef
78.
Alessandria C, Ottobrelli A, Debernadi-Venon W et al (2007) Noradrenaline vs. terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 47:499–505PubMedCrossRef
79.
Sharma P, Kumar A, Shrama BC et al (2008) An open label, pilot, randomized, controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 103:1689–1697PubMedCrossRef
80.
Lenz K (2012) Noradrenaline in the treatment of patients with hepatorenal syndrome. Back tot he roots? J Hepatol 57(4):925PubMedCrossRef
81.
Moore K (1997) The hepatorenal syndrome. Clin Sci 92:433–443PubMed
82.
Wong F, Sniderman K, Liu P et al (1995) Transjugular intrahepatic portosystemic shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med 122(11):816–820PubMedCrossRef
83.
Jalan R, Redhead DW, Thomas HW et al (1996) Mechanisms of changes in renal handling of sodium following transjugular intrahepatic portal systemic stent-shunt (TIPSS). Eur J Gastroenterol Hepatol 8(11):1111–1116PubMedCrossRef
84.
Gerbes AL, Gülberg V, Waggershauser T et al (1998) Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology 28(3):683–688PubMedCrossRef
85.
Brensing KA, Textor J, Perz J et al (2000) Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhosis with hepatorenal syndrome: a phase II study. Gut 47(2):288–295PubMedCrossRef
86.
Testino G, Ferro C, Sumberaz A et al (2003) Type 2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology 50(54):1753–1755PubMed
87.
Rössle M, Gerbes AL (2010) TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut 59(7):988–1000PubMedCrossRef
88.
Grandt D, Sauerbruch T, Reig W, Rössle M (2004) Therapie der portalen Hypertension. Dtsch Ärztebl 101(7):A416–A428
89.
Rössle M (2010) Early TIPS in patients with cirrhosis and variceal bleeding. Nat Rev Gastroenterol Hepatol 7:536–538PubMedCrossRef
90.
Heinzow HS, Lenz P, Köhler M et al (2012) Clinical outcome and predictors of survival after TIPS insertion in patients with liver cirrhosis. World J Gastroenterol 18(37):5211–5218PubMed
91.
Witzke O, Baumann M, Patschan D et al (2004) Which patients benefit from hemodialysis therapy in hepatorenal syndrome? J Gastroenterol Hepatol 19:1369–1373PubMedCrossRef
92.
Davenport A, Will EJ, Davidson AM (1993) Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 21(3):328–338PubMedCrossRef
93.
Wong LP, Blackley MP, Andreoni KA et al (2005) Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int 68(1):362–370PubMedCrossRef
94.
Pavelsky PM, Zhang HJ, O’Connor TZ et al (2008) Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 359(1):7–20CrossRef
95.
Bellomo R, Cass A, Cole L et al (2009) Intensity of continuous renal replacement therapy in critically ill patients. N Engl J Med 361(17):1627–1638PubMedCrossRef
96.
Piccinni P, Dan M, Barbacini S et al (2006) Early isovolaemic haemofiltration in oliguric patients with septic shock. Intensive Care Med 32(1):80–86PubMedCrossRef
97.
Rifai K, Manns M (2006) Review article: clinical experience with Prometheus. Ther Apher Dial 10(2):132–137PubMedCrossRef
98.
Gaspari R, Cavaliere F, Sollazzi L et al (2009) Molecular Adsorbent Recirculating System (MARS) in patients with primary nonfunction and other causes of graft dysfunction after liver transplantation in the era of extended criteria donor organs. Transplant Proc 41:253–258PubMedCrossRef
99.
Herrera-Gutierez ME, Seller-Perez G, Lebron-Gallardo et al (2007) Safety and efficiency of the MARS therapy applied by continuous renal replacement therapy (CRRT) monitors. Med Intensiva 31(7):367–374CrossRef
100.
Gonwa TA, Wadei HM (2012) The challenges of providing renal replacement therapy in decompensated liver cirrhosis. Blood Purif 33:144–148PubMedCrossRef
101.
Mitzner SR, Klammt S, Peszynski P et al (2001) Improvement of multiple organ function in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. Ther Apher 5:417–422PubMedCrossRef
102.
Mitzner SR, Strong J, Klammt S et al (2000) Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transplant 6:277–286CrossRef
103.
Wong F, Raina N, Richardson R (2010) Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. Gut 59:381–386PubMedCrossRef
104.
Cassinello C, Moreno E, Gozalo A et al (2003) Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis. Dig Dis Sci 48:179–186PubMedCrossRef
105.
Marik PE, Wood K, Starzl T (2006) The course of type1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant 21:478–482PubMedCrossRef
106.
Gonwa TA, Klintmalm GB, Levy M et al (1995) Impact of pre-transplant renal function on survival after liver transplantation. Transplantation 59:361–365PubMed
107.
Gonwa TA, Mai ML, Melton LB et al (2001) Endstage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy. Transplantation 72(12):1934–1939PubMedCrossRef
108.
Lee JP, Heo NJ, Joo KW et al (2010) Risk factors for consequent kidney impairment and differential impact of liver transplantation on renal function. Nephrol Dial Transplant 25(8):2772–2785PubMedCrossRef
109.
Ruiz R, Kunitake H, Wilkinson AH et al (2006) Long-term analysis of combined liver kidney transplantation at a single center. Arch Sarg 141(8):735–741CrossRef
110.
Restuccia T, Ortega R, Guevara M et al (2004) Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case control study. J Hepatol 40:140–146PubMedCrossRef
111.
Rice JP, Skagen C, Said A (2011) Liver transplantation outcomes for patients with hepatorenal syndrome treated with pre-transplant vasoconstrictors and albumin. Transplantation 91:1141–1147PubMedCrossRef
112.
Boyer TD, Sanyal AJ, Garcia-Tsao G et al (2011) Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transplant 17:1328–1332CrossRef
113.
Papafragkakis H, Martin P, Akahn E (2010) Combined liver and kidney transplantation. Curr Opin Organ Transplant 15:2063–2068CrossRef
114.
Locke JE, Warren DS, Singer A et al (2008) Declining outcomes in simultaneous liver-kidney transplantation in the MELD era: ineffective usage of renal allografts. Transplantation 85:935–942PubMedCrossRef
115.
Hartleb M, Gutkowski K (2012) Kidneys in chronic liver diseases. World J Gastroenterol 18(24):3035–3049PubMedCrossRef
Metadaten
Titel
Hepatorenales Syndrom
verfasst von
M. Hinz
O. Witzke
G. Gerken
Prof. Dr. A. Canbay
Publikationsdatum
01.07.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Nephrologie / Ausgabe 4/2013
Print ISSN: 2731-7463
Elektronische ISSN: 2731-7471
DOI
https://doi.org/10.1007/s11560-012-0737-5

Weitere Artikel der Ausgabe 4/2013

Der Nephrologe 4/2013 Zur Ausgabe

Leitthema

Kardiorenales Syndrom

Für Sie gelesen

Die gezüchtete Niere – schon bald Realität?

Leitthema

Niereninsuffizienz und Lungenfunktionsstörung im Wechselspiel

Leitthema

Kognitive Beeinträchtigung bei chronischer Nierenerkrankung

Im Fokus

CKD-MBD

CME Zertifizierte Fortbildung

Diabetische Nephropathie

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

22.05.2024 Obstipation Nachrichten

Bei chronischer Verstopfung wirken Kiwis offenbar besser als Flohsamenschalen. Das zeigen die Daten aus einer randomisierten Studie, die der Gastroenterologe Oliver Pech beim Praxis-Update vorstellte.

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise